Condition: Ulcerative Colitis, Pediatric · Inflammatory Bowel Diseases · Crohn Disease · Sponsor: University of North Carolina, Chapel Hill
The purpose of the study is to compare the clinical effectiveness and safety of newer inflammatory bowel disease (IBD) medications in anti-tumor necrosis factor (TNF) refractory patients with pediatric IBD (PIBD). Refractory means that there was no clinical response to anti-tumor necrosis factor (TNF) drugs or that the if there was a response, it is no longer present. The main question this study aims to answer is: Are the newer medications used to treat IBD just as safe and effective for treating IBD in children. Participants will already be taking these newer medications as assigned by their regular health care provider.Participants' care will be managed by their regular healthcare provider as part of usual (standard) care for those with PIBD. While taking these medications, participants will be asked to answer questions about their symptoms and health periodically over the course of the study.
This description comes directly from the study's public registry record.
Duke Clinical Research Institute COMPARE Call Center · 833-850-2848 · COMPARE@dm.duke.edu
Always discuss trial participation with your own doctor first.
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| Atrium Health | Charlotte, North Carolina, United States | Recruiting |
| Duke Health System | Durham, North Carolina, United States | Recruiting |
| University of Pittsburgh Medical Center, Children's Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07198113